Primary antiphospholipid syndrome (PAPS) is a systemic autoimmune disorder characterized by thromboembolic episodes and pregnant morbidity with an increasing clinical importance. To gain insight into the pathogenesis of PAPS, we have investigated the gene expression profiles that characterize peripheral blood mononuclear cells derived from PAPS patients. We show that the transcriptional activity of genes involved in innate immune responses, such as toll-like receptor 8 and CD14, as well as downstream genes of this pathway, such as STAT1, OAS2, TNFSF13 and PLSCR1 are significantly increased in PAPS patients. In addition, the expression of monocyte-specific cytokines is also elevated in PAPS mononuclear cells stimulated in vitro with lipopolysaccharide. Taken together, these results reveal a 'response to pathogen' signature in PAPS, which could reflect an altered monocyte activity. Finally, microarray analyses also revealed a reduced expression of genes coding for proteins involved in transcriptional control. Interestingly, a significant proportion of them exhibit E2F-binding sites in their promoter, suggesting that a deregulated RB/E2F activity could play a role in the pathogenesis of antiphospholipid syndrome.
Introduction
The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by elevated titers of circulating antibodies directed against phospholipidbinding plasma proteins (aPL), primarily beta 2-glycoprotein (b2GPI), or against phospholipids per se (that is, cardiolipin). [1] [2] [3] [4] These autoantibodies are not only markers of APS, but also believed to play pathogenic roles in the development of symptoms in patients with APS. [1] [2] [3] [4] APS was first fully described in the context of connective tissue autoimmune diseases, most usually systemic lupus erythematosus (SLE), although it was soon recognized that the condition can exist as an isolated, primary condition ('primary' APS, PAPS). 5, 6 Furthermore, patients with PAPS may subsequently develop SLE, implying a strong relationship between both conditions. However, the molecular basis of these autoimmune diseases has not been clarified. Recent gene expression profiling analyses have provided evidence for an interferon (IFN)-inducible gene expression signature in peripheral blood mononuclear cells (PBMCs) derived from lupus patients, thereby supporting the hypothesis for an inflammatory basis of this disease. [7] [8] [9] [10] The role of inflammation on APS has not been established, although some aspects of its pathogenesis could involve inflammatory cells and mediators.
PAPS has emerged as the most common cause of acquired thrombophilia, and a major cause of pregnant morbidity. [1] [2] [3] [4] Thus, it is important to uncover the underlying pathways that are relevant to this condition, since they are likely to be a contributing factor for a significant proportion of patients with a variety of vascular conditions. However, the pathogenic mechanism of aPL-induced thrombosis is not fully understood. Endothelial cell (EC) activation seems to be essential in the pathogenesis of APS. Experiments carried out in vitro have shown that aPL antibodies recognize the autoantigen on endothelial monolayers in vitro, and, once bound, induce a procoagulant and proinflammatory phenotype with upregulation of adhesion molecules and secretion of proinflammatory cytokines and chemokines. 11 The endothelial signaling cascade that is triggered by aPL is comparable to that activated by lipopolysaccharide (LPS) or IL1, and includes nuclear factor-kB (NF-KB) translocation from the cytoplasm to the nucleus through the MyD88-dependent pathway, 11, 12 suggesting an infectious origin for PAPS. A procoagulant activity/tissue factor expression has also been reported in normal PBMCs and platelets induced by aPL in vitro, associated with simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. 13 Whether such proinflammatory and/or procoagulant pathways are activated in vivo in patients with APS remains to be established.
Genome-wide expression profiling involving microarrays has emerged as a powerful approach to study the pathogenesis of an increasing number of diseases. Previous microarray-based studies have shown that PBMCs are a good source to analyze gene expression profiles and identify genes relevant to the pathogenesis of several autoimmune diseases, such as SLE, multiple sclerosis or rheumatoid arthritis. [7] [8] [9] [10] Given the evidence for a role of peripheral blood cells on autoimmunity, we have explored the transcriptome profiles of PBMCs derived from individuals with PAPS, and compared them with those of healthy individuals. We have found that PBMCs of PAPS patients exhibit gene expression patterns that are compatible with a proinflammatory and procoagulant activity, revealing a role for blood monocytes in the pathogenesis of this disease. Furthermore, a comparison of transcriptome profiles in PAPS and SLE patients has revealed an IFN-response signature that is shared by both diseases, whereas functional processes such as 'nucleic acid metabolism', 'response to wounding' or 'cell proliferation' appear to be specific to PAPS.
Results

Immunophenotypical and functional characterization of peripheral blood subpopulations in PAPS samples
Immunophenotypical characterization of peripheral blood cells in PAPS patients (PAPS1-6) showed a significant reduction in the absolute numbers of peripheral blood CD3 þ T lymphocytes compared to healthy controls (C1-6) (16737615 cells mm À3 vs 25147950 cells mm À3 , Po0.05), indicating moderate lymphopenia. By contrast, the number of B cells, monocytes, polymorphonuclear cells and NK cells was similar in patients and healthy individuals, and no leukopenia was detected in patients' blood samples. Serological characteristics of study cohorts are summarized in Table 1 , and a more detailed description of each patient, including clinical manifestations and treatment, is provided in Supplementary Table 1. The number of blood cells with a regulatory phenotype did not change in PAPS patients. Similarly, the expression of activation or adhesion molecules on CD4 þ or CD8 þ blood T cells in patients with PAPS was unchanged relative to healthy individuals, whereas CD4 þ and CD8 þ cells with a memory phenotype were increased in PAPS (Table 2) , a common feature of autoimmune disorders. 14 Next, we examined the activation potential of PBMCs derived from PAPS patients by measuring cytokine production after in vitro stimulation. Interestingly, we found that the expression of monocyte-specific inflammatory cytokines after in vitro activation with LPS (IL-1b, TNF-a and IL-6) was increased in PAPS patients (Figure 1a ). This response was restricted to monocytes, because T cells activated in vitro with phorbol esters and ionomycin in parallel experiments did not express higher intracellular levels of IFN-g (Figure 1a ). These results suggested that the monocyte subset could be affected in APS.
Deregulation of apoptotic cell death, either by increased apoptotic death or by defects in apoptotic cell clearance, has been proposed as a mechanism contributing to autoimmune disorders, such as SLE. 15 Blood cells of PAPS patients (PAPS1-6) also showed an increased proportion of apoptotic cells. Propidium iodide staining revealed that 10% of mononuclear cells purified from blood of patients with PAPS were apoptotic, relative to a 2.5% of cells from healthy subjects (Figure 1b) , suggesting an altered regulation of apoptosis in this disease.
Differences in global gene expression profiles between PAPS and healthy individuals
To explore gene expression patterns that could account for the pathogenesis of PAPS, and to identify biomarker genes capable of discriminating PAPS patients from healthy controls, we made use of microarray-based largescale gene expression analyses of mononuclear cells derived from peripheral blood of six PAPS patients (PAPS1-6) and of six healthy individuals (C1-6). PBMC cRNA was hybridized to U133A Affymetrix oligonucleotide microarrays. Genes that were not expressed in PBMCs were not considered for subsequent analysis, and of the remaining genes, 50% of those with the highest variance were selected, which yielded a total of 7235 microarray probes that were further examined.
Our data analysis identified a total of 96 probes (corresponding to 93 genes) differentially expressed between the two comparing groups of PAPS and healthy individuals (Welch's t-test, Po0.01, based on all possible permutations). Of these, 44% exhibited an increased expression and 56% exhibited a decreased expression in PAPS relative to controls. The complete list of differentially expressed genes, including Affymetrix probe IDs, Table 2 .
Since PAPS and SLE are closely related autoimmune diseases, we reasoned that a comparison of gene expression profiles between patients affected with PAPS and patients affected with SLE could reveal unique as well as common genes and pathways that are altered in these conditions. Transcriptome profiles of five SLE patients (SLE1-5) were obtained, and a total of 91 probes (corresponding to 88 genes) were identified as being differentially expressed between SLE and healthy controls (C1-6) (Welch's t-test, Po0.01, based on all possible permutations). Of these, 61% were overexpressed and 39% were underexpressed. Supplementary Table 3 includes a complete list of these genes.
Overrepresentation of genes involved in innate immune response and blood coagulation in PAPS Gene ontology analysis was used to classify the genes differentially expressed in PAPS and in SLE on the basis of their functional roles, allowing for identification of disease-specific genomic signatures. Moreover, in order to gain insight into the potential biological relevance of the altered gene expression patterns, Expression Analysis Systemic Explorer (EASE) analysis was performed, a software program that examines overrepresented biological processes within a selected gene list (see Materials and methods section).
Gene ontology annotation led to the identification of nine overrepresented biological categories in PAPS (Table 3 ). The most numerous overrepresented biological process was the category related to nucleic acid metabolism. This category included transcription factors, coactivators and repressors, zing finger proteins, splicing factors and proteins involved in maintenance and establishment of chromatin structure, such as histones and histone modification proteins. Notably, a large proportion of genes coding for proteins included in this category were downregulated in PAPS patients (Table 3) . Thus, transcriptional control appears to be altered in PAPS.
Remarkably, five out of nine overrepresented categories were related to innate immune responses. Included in these categories were type I IFN-induced genes (LGALS3BP, WARS, OAS2, G1P2, GTPBP2, TNFSF13, PLSCR1, H1F0, STAT1), all of which had an increased expression in patients with PAPS, and type II IFN-regulated genes (APOE, NCF2) ( Table 3 ), implying that the activation of the IFN pathway could be of relevance for the pathogenesis of PAPS. Importantly, these categories included several receptors (toll-like receptor 8 (TLR8), CD14, CD163, LGALS3BP) and genes required for monocyte function (STAT1, ATP6V1B2, Figure 1 Characterization of peripheral blood subpopulations in control and primary antiphospholipid syndrome (PAPS) samples.
(a) Cytokine production in peripheral T lymphocytes and monocytes in PAPS (n ¼ 3) and healthy controls (n ¼ 6). IFN-g was measured in CD4 þ T-lymphocytes. IL1b, TNFa and IL6 were measured in monocytes. Cytokine production was assessed by intracellular staining followed by flow cytometry. Results are expressed as the ratio between cytokine levels after stimulation relative to unstimulated cells. (b) Apoptosis percentage in freshly isolated peripheral blood mononuclear cells. Apoptosis was measured in freshly isolated peripheral blood mononuclear cells derived from patients with PAPS (n ¼ 6) and healthy controls (n ¼ 10) by propidium iodide staining followed by flow cytometry. Box-plot components are: box, interquartile range; horizontal line, median; whiskers, 1.5 Â interquartile range.
Innate immunity in antiphospholipid syndrome I Bernales et al C3AR1, NCF2, NCF4, HCK). The expression of these genes was upregulated in patients with PAPS. Interestingly, another overrepresented process with biological relevance in the pathology of PAPS was 'response to wounding', which included genes of the innate immune response (CD14, TLR8, NCF2, C3AR1, LGALS3BP), and genes related to the activation of blood coagulation, namely the glycoprotein 1B alpha polypeptide (GP1BA), and the phospholipid scramblase 1 (PLSCR1) which is an IFN-inducible gene. Taken together, gene expression results, combined with in vitro functional data, suggest that monocyte-mediated innate immune responses could be important contributors of the pathogenesis of PAPS.
Gene ontology annotation of the differentially expressed genes in SLE revealed five overrepresented categories (Table 3) , four of which were in common between PAPS and SLE. Interestingly, these clusters were related to innate immune responses and included a large number of genes known to be regulated by IFN (e.g. OAS2, OAS3, MX1, IRF7). By contrast, functional groups related to 'nucleotide metabolism' and 'response to wounding' were only overrepresented in PAPS, and genes coding for receptors involved in monocytemediated responses, such as CD14, TLR8 and CD163 were specific to the PAPS transcriptome.
Verification of microarray data with quantitative RT-PCR
To verify the microarray data, we selected nine genes involved in immune responses and coagulation, with increased expression in PAPS, that is NCF4, TLR8, CD14, CD163, PLSCR1, TNFSF13, STAT1, G1P2, OAS2, to analyze their transcriptional activity by quantitative RT-PCR, as indicated in Materials and methods. Of the selected genes, five are known to be IFN-response genes, with an elevated expression in microarray data of SLE patients. [7] [8] [9] [10] The expression of these genes was examined in 17 healthy controls (C7-23), 7 patients with PAPS (PAPS7-13) and 12 patients with SLE (SLE6-17), none of which had been included in the microarray analyses. A set of patients affected with thrombotic events but without PAPS (THR1-5) was also included in these analyses, to control for the effect of thrombosis and/or treatment with anticoagulants in gene expression. TATAbox-binding protein (TBP) was used as an endogenous control for all the samples, because its levels do not change between patients and healthy individuals. As shown in Figure 2 , quantitative RT-PCR was able to confirm the microarray data. Statistical analysis by oneway ANOVA followed by simple contrast showed that the relative expression of all nine genes was significantly elevated in PAPS patients compared to healthy controls (Po0.01 in all cases). The expression of these genes was also higher in PAPS relative to patients with thrombosis without APS, even though the expression of TLR8, NCF4 or CD163 was already elevated in thrombotic patients. A comparison between PAPS and SLE revealed no differences in the expression of five genes. However, significant differences were observed in the relative expression of the IFN-regulated genes PLSCR1 and TNFSF13, and the monocyte-specific receptors CD14 and TLR8 (Figure 2) , confirming both the unique and the similar molecular features of both conditions.
Analysis of transcription factor binding motifs (TFBMs)
in genes with deregulated expression in PAPS Genes involved in the same molecular pathway are often regulated by the same transcription factors and share regulatory sequences in their promoters. With this in mind, we searched for transcription factor-binding motifs that could be overrepresented in the deregulated genes identified in PAPS patients. Transcription Element Listening System (TELiS) analysis revealed two overrepresented transcription factor-binding motifs, the IFN alpha response element and the E2F binding motif. The IFN alpha response element ISRE (M000250-V$ISRE_01 motif from the TRANSFAC database), which is present in promoters of genes activated in response to IFN alpha, Figure 2 Quantitative real time RT-PCR analysis in samples of primary antiphospholipid syndrome (PAPS), systemic lupus erythematosus (SLE) and thrombosis patients. Gene expression of NCF4, TLR8, CD14, CD163, PLSCR1, TNFSF13, STAT1, G1P2 and OAS2 were analyzed by quantitative RT-PCR in healthy controls (n ¼ 17), PAPS patients (n ¼ 7), SLE patients (n ¼ 12) and thrombosis patients (n ¼ 5). In each case, expression values are normalized to the expression of TATA-Box-Binding Protein, used as an internal control. Box-plot components are: box, interquartile range; horizontal line, median; whiskers, 1.5 Â interquartile range. Asterisk denotes statistically significant differences between PAPS and any of the other groups (Po0.05, one-way ANOVA simple contrast).
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I Bernales et al was enriched 3.6-fold in the number of binding sites per promoter (frequency) (z-test P ¼ 0.0009), and 3.7-fold in the percentage of promoters with this binding site (incidence) (exact binomial test P ¼ 0.0056). Six genes exhibited this binding site in their promoters (OAS2, TLR8, WARS, STAT1, PHF3, TGIF), consistent with the finding of an IFN signature in PAPS. Interestingly, numerous genes differentially expressed in PAPS were enriched in E2F motifs (M00050 accession number of the TRANSFAC database), with an enrichment factor of 2.5 in frequency (z-test, P ¼ 1.38E-5), and an enrichment factor of 2.3 in incidence (exact binomial test, P ¼ 0.0005). By contrast, no enrichment in E2F motifs was detected in genes that were differentially expressed in SLE. Nearly a quarter (21.7%) of all the differentially expressed genes in PAPS had E2F motifs in their promoters (CDC7, FN5, UQCRB, DHODH, DKFZP564O0523, DYSF, JMJD2C, H1F0, TMEM41B, LPHN1, LOC283677, EXOSC9, HCK, PPM1B, SLC1A5, UNC84A, WARS, ZFX, ZNF43). The enrichment for this binding site was higher in promoters of genes with decreased expression (3.2 in frequency, z-test P ¼ 2.56E-6; 3.0 in incidence, exact binomial test P ¼ 0.0003). Thirteen of the nineteen genes with E2F binding sites were downregulated, and six of them were included in the GO category of 'nucleobase, nucleoside, nucleotide and nucleic acid metabolism' (chromatin remodeling proteins, transcription factors, RNA processing factors). These results underscore the importance of cell cyclecontrol proteins in the pathogenesis of the APS.
Discussion
In this study, we have used gene expression profiling of PBMCs in an attempt to define transcriptional patterns that discriminate PAPS patients from healthy individuals. Gene expression data indicate that a monocyterelated gene expression signature is prominent in patients suffering from PAPS, which could reflect an increased activation state of this cell subset. The elevated production of IL1b, IL6 and TNFa upon LPS stimulation by mononuclear cells of patients is also consistent with a monocyte-elicited inflammatory response in PAPS.
A pattern of IFN exposure in the blood cells of PAPS patients was evident in our data analysis. A significant number of type I IFN-target genes with an upregulated level of expression were detected in PAPS. Importantly, many of these IFN-targets represent molecules that have been associated with the pathogenesis of autoimmune diseases such as SLE, juvenile dermatomyositis, psoriasis or Sjogren's syndrome, [7] [8] [9] [10] 16, 17 which has led to the identification of the so-called 'interferon signature' in these autoimmune conditions. Our findings confirm that the IFN pathway is relevant in SLE, and reveal that this pathway is also prominent in PAPS. Thus, type I IFN, which is produced during the innate immune response, is likely to be a common pathogenic mediator of a number of alterations in the immune system, both in systemic as well as in organ-specific autoimmune diseases. Genes regulating inflammatory processes have also been identified in an extensive DNA microarray analysis involving APS patients. 18 Consequently, the development of therapies that inhibit the consequences of IFN production would reduce the adverse inflammatory effects of IFN, and could be beneficial for people suffering from APS.
Our results confirm previous observations that thrombosis and/or treatment with anticoagulants may have an effect in the expression of certain genes. 19 However, the gene expression changes associated with APS revealed in our work are significantly higher that the changes associated with thrombosis and/or use of anticoagulants, suggesting that the altered expression of these genes is, at least in part, specific to PAPS.
Antiphospholipid antibodies are thought to play a pathogenic role in APS by unknown mechanisms. Recently, these antibodies have been found to activate ECs and monocytes in vitro.
11-13 Anti-b2GPI antibodies display a MyD88-mediated signaling cascade comparable to the innate immune response activated by infectious agents in these cells, which could lead to the APS. We now demonstrate that TLR8, a TLR family member present in myeloid DCs, monocytes and monocyte-derived DCs, but not plasmacytoid DCs and specific for GU-rich ssRNA of viral origin, 20, 21 has an increased expression in PAPS. Furthermore, the elevated number of genes related to pathogen responses that are aberrantly expressed in PAPS, such as CD14, CD163 or NCF4 supports the notion of a TLR8-mediated activity in monocytes or monocyte-derived DCs that could be altered in this disease. Notably, this set of genes is not overexpressed in SLE, suggesting that it represents a PAPS-specific gene signature that could be elicited by infectious agents combined with antiphospholipid antibodies.
Interestingly, V-type ATPase, an enzyme responsible for endosome acidification, which is a necessary step for TLR8-mediated signaling, 22 is upregulated in PAPS patients. This enzyme is the therapeutic target of Chloroquine, an effective treatment for autoimmune diseases such as SLE and RA, 23, 24 which is also administered to some PAPS patients (see Supplementary  Table 1 ). Its therapeutic effect may be due, in part, to its ability to interfere with TLR8-mediated signals that contribute to autoantibody production or to the production of proinflammatory mediators.
Besides the potential activation by viral RNA, apoptotic cells may also play an important role in the stimulation of TLR8. Single-stranded RNA molecules bound to RNPs, which are frequently concentrated in the membranes of apoptotic cells, have been found to stimulate TLR8. 25 Furthermore, the phospholipids that bind b2GPI and constitute the major autoantigen in PAPS are only exposed on the external surface of the plasma membrane after the cell has undergone apoptosis. 26 Thus, the increased proportion of apoptotic cells that we have found in PAPS blood cells could elicit the activation of TLR8-mediated responses in monocytes of these patients. A similar mechanism involving plasmacytoid dendritic cells has been suggested for SLE and Sjogren's syndrome, although such a mechanism seems to be associated to TLR9 activation by dsDNA molecules exposed on the plasma membrane of apoptotic cells. 17, 27 The upregulated expression of phospholipids scramblase (PLSCR1), a member of a family of membrane proteins that contributes to the reorganization of plasma membrane phospholipids occurring upon cell injury or apoptosis 28 or the upregulation of LGALS and CD14, two receptors involved in the clearance of apoptotic cells, provides a link between our observations in PAPS with dysregulation of apoptosis and/or handling of apoptotic cells.
An interesting finding revealed by the microarray analysis is the altered expression of genes included in the category of nucleotide metabolism, coding for transcription factors and proteins involved in splicing and chromatin regulation. This suggests that a general mechanism regulating nucleic acid metabolism is altered in PAPS. The implication of this phenomenon in the pathogenesis of the disease is presently unknown, but it could contribute to the increased apoptotic rate observed in blood cells, perhaps as a consequence of some type of genomic instability.
Interestingly, many of the genes included in this category exhibit E2F-binding sites in their promoters. E2F transcription factors regulate the expression of genes involved in cell cycle control as well as in chromatin condensation, DNA damage repair and apoptosis. 29 Our data suggest that an altered RB/E2F pathway could account for the reduced expression of the target genes in PAPS. Incidentally, a link between E2F and autoimmunity has previously been described, whereby inactivation of some E2F family members in mice has been found to result in tolerance loss and autoimmunity. 30, 31 It is tempting to speculate that E2F activity could be repressed in patients with PAPS by factors known to contribute to the formation of transcriptional repressor complexes involving E2F, including members of the Retinoblastoma family of pocket proteins, histone deacetylates and DNA methyltransferases. 32 An analysis of the repressor activity of these complexes in PAPS patients could provide some clues about the nature of the transcriptional profile observed, and their involvement in the pathogenesis of the disease.
Materials and methods
Patients
Thirteen PAPS patients fulfilling the revised Sapporo criteria, 33 seventeen SLE patients fulfilling the revised American College of Rheumatology classification criteria, 34 five thrombotic patients with no APS and 23 healthy controls, all Caucasian women, were enrolled in our study after institutional review board approval (Table 1  and Supplementary Table 1 ). Time range of blood collection from clinical episode for PAPS and thrombosis patients was 2-68 months. No patients were under immunosuppressant therapy.
Quantitation of serum antiphospholipid antibodies (anticardiolipin and anti-b2GPI) was performed in duplicate by enzyme-linked immunosorbent assay (ELI-SA). The ELISA for anticardiolipin antibodies was carried out in the presence of the b2GPI cofactor, as recommended by internationally established guidelines. 35 Lupus anticoagulant was determined by a standard coagulation test as established. 35, 36 Briefly, a prolonged coagulation time was demonstrated by two tests (Activated Partial Thromboplastin Time, APTT, and dilute Russell's Viper Venom Time, dRVVT), and the assay was considered positive when confirmed in two assays at least 12 weeks apart. Serum C3 and C4 were quantified by nephelometry (Dade Behring, Marburg, Germany).
Phenotypic analysis and functional assays Blood cells were stained with mAb against cell-surface markers (Becton-Dickinson Biosciences, San Jose, CA, USA) and analyzed on a FACScalibur flow cytometer using CellQuest Pro software (BD Biosciences).
Cytokine production was measured by intracellular staining and flow cytometry analysis. Peripheral blood lymphocytes were stimulated with phorbol myristate acetate and ionomycin in the presence of brefeldin A for 4 h and, thereafter, collected and stained with mAbs for surface CD4 and intracellular IL-2, IFN-g and IL-4, as previously described. 37 For monocyte stimulation, whole blood cells were treated with LPS for 4 h, and, thereafter, collected and stained simultaneously with mAbs for surface CD14 and intracellular IL-1, IL-6 and TNF-a, to analyze specifically the monocyte subset. Statistical analysis was performed using the Mann-Whitney U test at a significance level of Po0.05 with SPSS 14.0 program.
Apoptosis measurement
Apoptosis was analyzed on freshly isolated PBMCs by propidium iodide staining (0.1 mg ml À1 propidium iodide in 0.1% sodium citrate plus 0.01% Triton X-100 and 50-70 U ml À1 of RNAse A) for 30 min at 37 1C. Apoptosis was measured on a FACSCalibur flow cytometer (BD Biosciences). Statistical analysis was performed using the Mann-Whitney U test at a significance level of Po0.05 with SPSS 14.0 program.
Sample preparation and microarray hybridization
Fresh PBMCs were isolated from heparinized venous blood by centrifugation on a Ficoll-Paque PLUS (GE Healthcare Bio-Sciences, Piscataway, NJ, USA). Total RNA from PBMCs was isolated with TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) followed by RNeasy MinElute cleanup (QIAGEN, Valencia, CA, USA). Target preparation and microarray hybridization were carried out with the Affymetrix GeneChip System (Affymetrix, Santa Clara, CA, USA) at PROGENIKA Biopharma (Zamudio, Bilbao, Spain) as described. 38 Human Genome U133A microarrays (Affymetrix), containing probes for 18 400 transcripts and variants were used in this study. Affymetrix Microarray Suite (MAS) 5.0 software was used for data normalization. Preprocessed data were filtered to select 50% of the genes with the highest variance (s.d.). To identify the genes whose expression levels differ significantly between patients and normal controls we used the Welch's t-test. The P-value was based on all possible permutations, and the significance level cut-off was Po0.01, to reduce the number of false positives.
Gene annotation and biological process categorization
We used the DAVID database for functional annotation and categorization of genes. 40 Gene categories were tested statistically with the EASE (Fisher's exact test) 41 to identify overrepresented or enriched categories of identified genes when compared to the background gene list (all the genes in the microarray). Enriched functional categories were those with the number of list hits of at least 2, with a P-valueo0.05 (EASE, Fisher's exact test).
Quantitative RT-PCR assays Purified total RNA was retrotranscribed to cDNA using random hexamers and the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen), according to manufacturer's instructions. Real-time PCR reactions were performed using TaqMan Gene Expression Assays from Applied Biosystems (ABI, Foster City, CA, USA) for each gene (CD14, Hs00169122_g1; CD163, Hs00174705_ml; G1P2, Hs00192713_ml; OAS2, Hs00159719_ml; STAT1, Hs00234829_ml; TNFSF13, Hs00601664_g1; PLSCR1, Hs00275514_m1; TLR8, Hs00152972_m1; NCF4, Hs00241129_m1; TBP, Hs00427620_m1). The reactions were run by triplicate on an ABI 7900HT Fast Real-Time PCR System using standard cycling conditions, at the Genomics Facility of the UPV/EHU. Results were analyzed with the Sequence Detection System (SDS) Software v2.2.1 (Applied Biosystems) to obtain the Ct values for each sample. Statistical analyses were performed using one-way ANOVA simple contrasts to carry out comparisons among groups at a significance level of Po0.05 with SPSS 14.0 program.
Analysis of TFBMs
We used the TELiS to find overrepresented TFBMs in the promoters of the differentially expressed genes in PAPS, 42 using the TRANSFAC database of TFBMs. For each deregulated gene, a 1200 bp-length promoter sequence (À1000 to þ 200 relative to transcription start site) was considered for this analysis, with high stringency (0.90).
